SD Biosensor, Inc (137310) Fair Value & Analysis
Healthcare · KR · Market cap 855B KRW
Analysis
SD Biosensor, Inc (137310) currently trades at 6,070 KRW, while our model-based Fair Value estimate is 3,856 KRW — implying the stock looks roughly 36.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
SD Biosensor, Inc., together with its subsidiaries, operates as an in-vitro diagnostic company in South Korea, India, Asia, Europe, the Americas, and Africa. The company offers STANDARD Q, which provides rapid diagnostic products; STANDARD F, a fluorescence immunodiagnostic system for various qualitative and quantitative diagnosis items; STANDARD E, an enzyme immunoassay diagnosis for large-volume tests; and STANDARD M, a field molecular diagnosis system for infectious disease diagnosis, drug resistance, and genetic testing. It also provides STANDARD i, an analyzer based on chemiluminescence immunoassay technology for detection of clinical biomarkers, including hormones, tumor markers, and infectious diseases; blood glucose meter products; and other products, such as transport medium, d-BLOCK incubator, G6PD analyzer, LipidoCare analyzer, MultiCare analyzer, and Pilot COVID-19 at-home test. The company exports its products. SD Biosensor, Inc. was founded in 1999 and is headquartered…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.